Get started
Author

Jurgita Juršėnaitė

Observed names: JURGITA JURSENAITE, JURGITA JURŠĖNAITĖ, Jurgita Jursenaite, Jursenaite Jurgita
ORCID: 0000-0002-2888-2362
Observed ORCID: 0000-0002-2888-2362
OpenAlex ID: A5065540198
Prognostic significance of soluble PD-L1 in prostate cancer
2024 · Margarita Zvirble, Zilvinas Survila, et al. · Frontiers in Immunology · 12
PDF
Expanded effector memory T-lymphocytes in DBA/2 mice do not inhibit the growth of SL2 tumours.
2012 · Jurgita Jursenaite, Irute Girkontaite, et al. · PubMed · 2
Bioluminescence Imaging of Adoptively Transferred Lymphocytes During Allogeneic Tumor Rejection.
2015 · Jurgita Juršėnaitė, Irutė Girkontaitė, et al. · PubMed · 1
Accumulation of small peritoneal macrophages and dendritic cells in a concomitant immunity model associated with prolonged survival
2026 · Milda Vanagaitė-Žičkienė, Jurgita Juršėnaitė, et al. · Frontiers in Immunology
PDF
Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following AerosolizationviaMesh Nebulizer
2023 · GINTARAS ZALESKIS, MARTYNAS TALAIKIS, et al. · Anticancer Research
PDF
Thymus Subset Alterations Accompanying Concomitant Tumor Immunity Mimics Phenotypic Patterns of Cytotoxic Drug Doxorubicin
2022 · GINTARAS ZALESKIS, DAINIUS CHARACIEJUS, et al. · In Vivo
PDF
Intratumoral Accumulation and Clonal Expansion May Not Be Decisive for Rejection of Allogeneic Tumors by CD8+ T-Lymphocytes
2018 · JURGITA JURŠĖNAITĖ, IRUTĖ GIRKONTAITĖ, et al. · Anticancer Research
PDF
The role of memory T lymphocytes during growth of SL2 tumours in DBA/2 mice
2013 · Jursenaite Jurgita, Mauricas Mykolas, et al. · Frontiers in Immunology
Works count: 8
Citation count: 15
H-index: 2
I10-index: 1
Year
Topic
Type